ADRIANA is a selective ñ<sub>2B</sub>-adrenergic receptor antagonist. It is described as highly selective over the ñ<sub>2A</sub>- and ñ<sub>2C</sub>-adrenergic receptors. The drug stimulates norepinephrine release in the spinal dorsal horn and has potent analgesic effects in rodents and non-human primates. It is orally active. ADRIANA was first described in the scientific literature by Masayasu Toyomoto and colleagues in 2025. It is said to be the first selective ñ<sub>2B</sub>-adrenergic receptor antagonist to have been developed.